A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer
Mohamed A. Gouda(The University of Texas MD Anderson Cancer Center), Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Vasudha Katragadda(Cornerstone University), Alice C. Fan(Stanford Medicine), Shailender Bhatia(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Richard J. Lee(La Roche College), Petros Nikolinakos(University Cancer and Blood Center), Geoffrey I. Shapiro(Brigham and Women's Hospital), Nizar M. Tannir(The University of Texas MD Anderson Cancer Center), Michael S. Gordon(Pinnacle Oncology Hematology), Jorge Chaves(Northwest Medical Specialties), Ulka N. Vaishampayan(University of Michigan), Elaine T. Lam(University of Colorado Cancer Center), Martin H. Voss(Memorial Sloan Kettering Cancer Center), Hussein A. Tawbi(The University of Texas MD Anderson Cancer Center), D. McDermott(Beth Israel Deaconess Medical Center), Scott S. Tykodi(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa)
Cited by 54
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k